PROCEPT BioRobotics (PRCT) Q4 2024: 57% Revenue Surge Amid Hydros Launch and Saline Supply Challenges
PROCEPT BioRobotics delivered substantial revenue growth driven by the successful commercial launch of its next-generation Hydros robotic system despite a saline shortage disrupting elective procedures. The quarter's momentum and expanded installed base set the stage for accelerated adoption and margin expansion in 2025, supported by a robust clinical pipeline targeting prostate cancer.
Summary
- Innovative Product Adoption: Hydros system launch exceeded expectations, driving strong capital sales and procedural efficiency improvements.
- Operational Resilience: Company navigated a significant saline shortage that delayed up to 20% of procedures without losing market share.
- Strategic Clinical Advancement: Initiation of pivotal prostate cancer trial positions PROCEPT for growth beyond BPH treatment.
Business Overview
PROCEPT BioRobotics is a surgical robotics company specializing in urology, primarily developing robotic systems for Aquablation therapy to treat benign prostatic hyperplasia (BPH). The company generates revenue through robotic system sales, handpieces and consumables, and service contracts, with major segments including U.S. system sales, consumables, and growing international operations.
Performance Analysis
In Q4 2024, PROCEPT reported total revenue of $68.2 million, marking a 57% increase year-over-year, fueled by a 67% surge in U.S. system revenue to $27.6 million and a 36% rise in handpiece and consumable sales. The installed base grew to 505 systems in the U.S., a 60% increase from the prior year, reflecting strong adoption of the Hydros robotic system, which accounted for 95% of system sales in the quarter. International revenue more than doubled, climbing 137% to $7.8 million, primarily driven by the United Kingdom.
Gross margin expanded significantly to 64%, up from 49% a year earlier, driven by higher average selling prices (ASP) for Hydros systems and improved operational efficiencies. Operating expenses rose 25% year-over-year to $63.4 million, reflecting investments in commercial expansion and increased variable compensation, yet operating expense growth lagged revenue gains, underscoring improving leverage. Net loss narrowed to $18.9 million, with adjusted EBITDA loss improving to $10.3 million, signaling progress toward profitability.
- Revenue Growth Drivers: Hydros system sales and increased procedural volumes at higher ASPs were key growth levers.
- Margin Expansion: Improved overhead absorption and premium pricing contributed to a 1500 basis point gross margin increase.
- Operational Headwinds Managed: Saline shortages caused estimated delays or cancellations of up to 2,000 procedures, impacting handpiece demand.
Despite the saline supply disruption, PROCEPT demonstrated operational resilience by proactively rescheduling procedures and optimizing commercial efforts, setting a foundation for 2025 growth.
Executive Commentary
"The market receptivity of Hydros has exceeded expectations, manifesting into a robust capital pipeline and higher selling prices. The introduction of First Assist AI enhances procedural accuracy and surgeon experience, positioning Hydros as a platform for future innovation."
Reza Zadno, Chief Executive Officer
"Our 2024 results reflect strong operating expense leverage with revenues growing 65% against 30% operating expense growth. We expect to generate net interest income in 2025 and project adjusted EBITDA loss to narrow further, underscoring a clear path to profitability."
Kevin Waters, Chief Financial Officer
Strategic Positioning
1. Next-Generation Hydros System as Growth Catalyst
The Hydros robotic system, cleared by the FDA in August 2024, integrates advanced ultrasound and AI-powered First Assist technology to improve procedural precision and streamline operating room workflow. This innovation enhances the user experience for surgeons and hospital staff, while the single-use digital scope reduces reprocessing costs. The commercial launch's success is evidenced by 60 system sales in Q4 and a higher average selling price of approximately $460,000, signaling strong market acceptance and pricing power.
2. Expanding U.S. and International Market Penetration
PROCEPT continues to expand its U.S. installed base aggressively, targeting a modest 10% share of the BPH-receptive market, which comprises approximately 2,700 hospitals. The company is also scaling international operations, with the United Kingdom showing strong momentum and Japan poised for growth following reimbursement establishment. This geographic diversification supports sustained revenue growth and long-term market development.
3. Clinical Innovation Targeting Prostate Cancer
PROCEPT is pioneering Aquablation therapy's application to localized prostate cancer, having secured FDA Investigational Device Exemption (IDE) approval for the WATER-4-PCA pivotal randomized trial comparing Aquablation to radical prostatectomy. This trial, enrolling 280 patients with up to 10 years of follow-up, aims to establish Aquablation as a first-line surgical option for prostate cancer, potentially unlocking a significant new market beyond BPH treatment.
4. Operational Agility Amid Supply Chain Disruption
The saline shortage caused by Hurricane Helene disrupted elective procedures, particularly in November 2024, delaying or canceling an estimated 10% to 20% of Aquablation surgeries. PROCEPT responded by rescheduling cases and refocusing commercial efforts, mitigating the impact on handpiece sales and maintaining customer relationships. This adaptability underscores operational strength in managing external shocks.
5. Financial Discipline and Path to Profitability
Management's disciplined expense growth, combined with gross margin expansion to mid-60% levels, supports a narrowing net loss and adjusted EBITDA loss. The 2025 guidance anticipates 42% revenue growth to $320 million, gross margins of approximately 64.5%, and adjusted EBITDA loss reduction to $35 million. Investments in clinical trials and commercial expansion are balanced with a strong cash position of $334 million, providing flexibility for growth initiatives.
Key Considerations
The fourth quarter highlighted PROCEPT's ability to balance rapid growth with operational challenges and strategic investments. Key considerations for investors include:
- Hydros Adoption Momentum: Continued strong demand and positive customer feedback suggest sustained revenue growth, but pricing variability may cause quarter-to-quarter fluctuations.
- Procedure Volume Recovery: The saline shortage impact is largely behind, with February and March showing robust procedural rebound, supporting handpiece sales recovery.
- Replacement Market Potential: Early-stage replacement sales are modest but expected to grow, representing a meaningful long-term revenue driver as installed base ages.
- Clinical Trial Investment: Front-loaded expenses for the WATER-4-PCA trial increase operating costs in 2025 but position PROCEPT to capture prostate cancer treatment opportunities.
- International Expansion: The UK and Japan markets offer significant upside, though revenue contribution remains a smaller portion of total sales currently.
Risks
PROCEPT faces risks including reliance on elective procedure volumes susceptible to macroeconomic and supply chain disruptions, such as the saline shortage experienced in Q4. Competitive dynamics in urology, reimbursement changes, and the uncertain timing and outcome of clinical trials for prostate cancer indications also present uncertainties that could affect future growth and profitability.
Forward Outlook
For Q1 2025, PROCEPT projects approximately $65.5 million in total revenue, including $18.7 million in U.S. system revenue and sales of around 10,750 handpieces. Gross margin guidance is approximately 64%, with operating expenses near $71 million.
Full-year 2025 guidance anticipates:
- Revenue growth to approximately $320 million, a 42% increase over 2024
- Gross margin expansion to roughly 64.5%
- Operating expenses around $300 million, reflecting strategic investments
- Adjusted EBITDA loss narrowing to approximately $35 million
Management emphasized ongoing investments to accelerate clinical trial enrollment and commercial execution, while maintaining a cautious outlook on procedure utilization recovery post-saline shortage.
Takeaways
PROCEPT BioRobotics is capitalizing on its innovative Hydros platform to drive robust growth and margin expansion, despite external challenges. The company's strategic focus on clinical differentiation and geographic expansion underpins its long-term opportunity in urology.
- Robust Growth Engine: Hydros system adoption and handpiece sales growth are validating PROCEPT's market penetration strategy and pricing power.
- Clinical Differentiation: The WATER-4-PCA prostate cancer trial represents a potential inflection point, expanding the company's addressable market beyond BPH.
- Operational Resilience: Effective management of supply chain disruptions and commercial agility support a positive procedural recovery trajectory.
Conclusion
PROCEPT BioRobotics' Q4 2024 results reflect successful execution of its next-generation robotic system launch amid temporary headwinds. The company’s expanding installed base, margin improvement, and clinical innovation position it well for accelerated growth and eventual profitability in the evolving urology market.
Industry Read-Through
PROCEPT’s experience underscores the importance of technological innovation and clinical validation in surgical robotics, particularly in urology. The integration of AI and streamlined procedural workflows in Hydros may set new standards for efficiency and outcomes. The saline shortage highlights the vulnerability of elective procedure-dependent businesses to supply chain shocks, a risk other medtech companies should monitor closely. Additionally, PROCEPT’s pioneering prostate cancer trial could catalyze broader adoption of minimally invasive robotic therapies, influencing competitive dynamics and reimbursement landscapes across the sector.